Autopsy report · NCT02748564

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study Complete”

The sponsor’s own words in the registry.

Life of this trial

Registered 11 months before it started.
Ran for about 6 years 2 months before it stopped.
10 participants enrolled.
Results were posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Rutgers, The State University of New Jersey
Sponsor type: University, hospital or other
Conditions: Metastatic Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma
Interventions: Aldesleukin; Laboratory Biomarker Analysis; Pembrolizumab
Participants: 10
Sites: 5
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.